BioCentury | Sep 22, 2020
Deals

Next up, NodThera? Roche’s €380M deal for Inflazome is latest NLRP3 takeout

...were at the forefront of discovering the broad potential of inflammasome inhibition. Co-founder and CSO Luke...
BioCentury | Aug 14, 2020
Finance

OSI leverages foundational deal with Oxford to build its life sciences portfolio

...as principal after being an associate and entrepreneur-in-residence at Atlas Venture. The firm recently added Luke...
BioCentury | Jul 21, 2020
Deals

With deal for Tizona, Gilead places latest bet on cancer immunosuppression

...CEO of Rubius Therapeutics Inc. (NASDAQ:RUBY). Clarke succeeded Cagnoni at Tizona in January 2019; MPM’s Luke...
BioCentury | Feb 27, 2020
Finance

MPM, Dana-Farber forge philanthropic arrangement around new oncology funds

...and Mal Salter, had long sought a solution. The idea was hatched years ago; MPM's Luke...
BioCentury | Feb 25, 2020
Distillery Therapeutics

Inhibiting stress response protein YCK2 to overcome antifungal resistance

...A team led by Bright Angel Therapeutics Inc. co-founder Leah Cowen, and including fellow co-founder Luke...
BioCentury | Nov 20, 2019
Financial News

Werewolf debuts with $56M to develop tumor-activated biologics

...conditionally activated cytokines, or Indukines, against well-validated targets, most likely in solid tumors. MPM Capital’s Luke...
BioCentury | Sep 24, 2019
Financial News

Amphivena to expand clinical program, T cell engager pipeline with $62M series C

...“AMV564 also eliminates the MDSC population rather than block biochemical pathways related to MDSCs.” MPM’s Luke...
BioCentury | Aug 23, 2019
Distillery Therapeutics

KRAS inhibitor combinations for improved therapeutic efficacy

...San Francisco, Calif. e-mail: kevan.shokat@ucsf.edu CONTACT: Luke Gilbert, University of California, San Francisco, Calif. e-mail: luke.gilbert@ucsf.edu Inhua...
BioCentury | Jun 25, 2019
Finance

Frontier aims for previously unreachable ‘hot spot’ targets with $67M series A

...of targets, while Roberto Zoncu has studied cellular function and growth regulation in cancer. MPM’s Luke...
...we can find our way to one or two ‘win-win’ kinds of deals relatively early.” Luke...
BioCentury | Apr 12, 2019
Product Development

NLRP3 early and often

...developers came with the creation of the tool compound MCC950 by Inflazome Co-founder and CSO Luke...
Items per page:
1 - 10 of 104